Scandi Standard publ AB (0QVR)
London Exchange · UK · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 178.40 |
|---|---|
| 52-week range | 94.65 – 184.80 |
| Return, 1 month / 3 months | +4.6% / +43.7% |
| Return, 1 year / 3 years | +102.1% / +302.4% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 32.1% |
| Worst drawdown (1 year) | -22.2% |
| Average daily value traded | 0.97M SEK |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Scandi Standard is a poultry company based in Stockholm, Sweden. It produces and sells chicken products, including fresh and frozen chicken, processed chicken items and ready-to-cook meals, under brands such as Kronfågel, Danpo and Manor Farm. Its customers are mainly grocery retailers, food service operators and the food industry in the Nordic countries and other European markets. The company also offers related food products and works with contract producers and its own processing facilities.
Scandi Standard publ AB trades under the code 0QVR on the London Exchange in UK, with its price quoted in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Scandi Standard publ AB (0QVR) trades on the London Exchange in UK. It last closed at SEK 178.40 on 23 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 500 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 102.1% and over the last three months it rose 43.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 30.6% | ||
| From 52-week high | -2.6% | ||
| Momentum | 91 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 43.7% | ||
| 6-month return | 18.0% | ||
| 12-month return, skipping the last month | 93.3% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.2% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.97M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 21 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +10.5% |
|---|---|
| 1 month | +4.6% |
| 3 months | +43.7% |
| 6 months | +18.0% |
| 1 year | +102.1% |
| 3 years | +302.4% |
| 5 years | +347.2% |
Signals
| 50-day / 200-day average | 156.37 / 136.62 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.83 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Sep 2026 | SEK 1.6500 |
| 29 Apr 2026 | SEK 1.6500 |
| 18 Sep 2025 | SEK 1.2500 |
| 30 Apr 2025 | SEK 1.2500 |
| 19 Sep 2024 | SEK 1.1500 |
| 3 May 2024 | SEK 1.1500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.